| P/E (FY) | — | Sales (TTM) | $1.0M |
| Earnings (TTM) | -$49.9M | ROE | −60.25% |
| Net Margin | −4880.90% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 15.32% |
| Market Cap | $523.0M | Trading Days | 1359 |
| 52W High | 8.33 |
| 52W Low | 0.71 |
| % Off High | −18.13% |
| YTD | 86.85% | 1Y | 730.69% |
| 3Y | 163.83% | 5Y | −69.31% |
| Since incept. (ann.) | −28.89% |
Reportable 100%
| Ann. Volatility (1Y) | 103.69% | Ann. Volatility (3Y) | 139.05% |
| Sharpe (1Y) | 2.59 | Sharpe (3Y) | 0.83 |
| Max Drawdown (1Y) | −50.51% | Max Drawdown (3Y) | −93.45% |
| Beta (3Y, vs SPY) | 1.46 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| MPLT | MapLight Therapeutics, Inc. | $522.4M | — |
| NGNE | Neurogene Inc. | $524.9M | — |
| NVCT | Nuvectis Pharma, Inc. | $525.7M | — |
| ARVN | ARVINAS, INC. | $529.1M | — |
| VSTM | Verastem, Inc. | $547.5M | — |
| RLMD | RELMADA THERAPEUTICS, INC. | $548.6M | — |
| SPRY | ARS Pharmaceuticals, Inc. | $563.0M | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $575.2M | 7.2 |
| CRMD | CorMedix Inc. | $576.6M | 3.6 |
| RZLT | Rezolute, Inc. | $473.8M | — |
| AQST | Aquestive Therapeutics, Inc. | $471.7M | — |
| GYRE |
| GYRE THERAPEUTICS, INC. |
| $581.2M |
| 58.8 |
